Literature DB >> 18434035

Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation.

Zhi-Yong Sun1, Li Yang, Cheng-Gang Yi, Huan Zhao, Da-Li Han, Tao Yang, Lu Wang, Chun-Lei Nie, Guo-You Zhang, Guo-Qian Yin, Gang Wang, Xiao-Pin Teng, Dong-Mei Fei, Jin Wang, Wen-Kai Zhou, Yang Li, Bin Liu, Yin Liu, Man-Jing Zhang, Shang-Min Wu, Xi Zhang, Hua Pan, Bo Xiao, Ke-Feng Zhao, Dan Liu, Shu-Zhong Guo.   

Abstract

Hemangiomas, often categorized as angiogenic diseases, are the most common tumors of infancy, the life span of which is generally divided into proliferating phase, involuting phase, and involuted phase. Despite their high prevalence, the mechanism leading to proliferation hemangiomas formation is poorly understood and the best approach to their management remains controversial. None of the current therapeutic modalities is ideal, partly because the pathogenesis of hemangioma and the mechanism of its proliferation are far from clear. Many clues reveal that estrogen has an important role in developing the vascular system, experimental and clinical evidences accumulated in recent years also suggest the potential for estrogen to influence neovascularization. Based on those, we hypothesize that estrogen play a potential role in the development of hemangiomas, mainly by regulating some key angiogenic factors, including MMP-9, EPCs, VEGF, NO, etc. Accepting the hypothesis to be correct, a therapy that identify estrogen as a potential target for the design of new, more specific treatments can be used to prevent the proliferation hemangiomas formation. The hypothesis may lead a new direction in the study of mechanisms for proliferation hemangiomas formation, and further study of the precise mechanisms for estrogen-induced hemangiomas will produce effective antiestrogens and estrogen receptor antagonists as new medication for the very difficult problem.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434035     DOI: 10.1016/j.mehy.2008.02.015

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

Review 1.  Vascular anomalies of the upper extremity.

Authors:  Benjamin J Jacobs; Alex Anzarut; Sara Guerra; Gayle Gordillo; Joseph E Imbriglia
Journal:  J Hand Surg Am       Date:  2010-10       Impact factor: 2.230

2.  Uterine Hemangioma Presenting as an Endometrial Polyp in a Postmenopausal Woman.

Authors:  Asad Ullah; Yulan Jin; Nivin Omar; Bisma Tareen; Elizabeth Pryor; Intisar Ghleilib
Journal:  Curr Health Sci J       Date:  2022-03-31

Review 3.  A Comprehensive Review of Hepatic Hemangioma Management.

Authors:  Hassan Aziz; Zachary J Brown; Azarakhsh Baghdadi; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2022-06-15       Impact factor: 3.267

Review 4.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

5.  A potential role for notch signaling in the pathogenesis and regulation of hemangiomas.

Authors:  June K Wu; Jan K Kitajewski
Journal:  J Craniofac Surg       Date:  2009-03       Impact factor: 1.046

6.  A rapidly enlarging cutaneous hemangioma in pregnancy.

Authors:  Marwan Ma'ayeh; Nikhil Purandare; Michelle Harrison; Michael P Geary
Journal:  Clin Pract       Date:  2014-10-08

Review 7.  A rare case of important and recurrent abnormal uterine bleeding in a post partum woman caused by cavernous hemangioma: a case report and review of literature.

Authors:  Kacou Edele Aka; Gninlgninrin Apollinaire Horo; Minata Fomba; Salif Kouyate; Abdoul Koffi Koffi; Seni Konan; Mohamed Fanny; Benjamin Effi; Mamourou Kone
Journal:  Pan Afr Med J       Date:  2017-10-10

8.  Estrogen is involved in hemangioma regression associated with mast cells.

Authors:  Fang Hou; Yuemeng Dai; Chun-Yang Fan; James Y Suen; Gresham T Richter
Journal:  Orphanet J Rare Dis       Date:  2018-10-19       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.